Research programme: monoclonal antibodies - Xencor

Drug Profile

Research programme: monoclonal antibodies - Xencor

Alternative Names: XmAb 14484; XmAb 18087; XmAb 20717; XmAb 5483; XmAb®5485

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Xencor
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD20 antigen inhibitors; CD20 antigen modulators; CD3 antigen inhibitors; CD3 antigen modulators; CD38 antigen inhibitors; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3-receptor-alpha-subunit-antagonists; PDCD 1 protein inhibitors; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; B cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Research Immunological disorders

Most Recent Events

  • 03 Nov 2016 Selexis and Xencor agree to co-develop multi-specific monoclonal antibodies
  • 02 Nov 2016 Xencor announces intention to submit IND to US FDA for XmAb®18087 in Neuroendocrine tumours in 2017
  • 02 Nov 2016 Xencor announces intention to submit IND to US FDA for XmAb®20717 in Cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top